Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To explore the genetic basis for a patient with Dilated cardiomyopathy.
Methods: A patient admitted to Beijing Anzhen Hospital Affiliated to Capital Medical University in April 2022 was selected as the study subject. Clinical data and family history of the patient was collected. Targeted exome sequencing was carried out. Candidate variant was verified by Sanger sequencing and bioinformatic analysis based on guidelines of the American College of Medical Genetics and Genomics (ACMG).
Results: DNA sequencing revealed that the patient has harbored a heterozygous c.5044dupG frameshift variant of the FLNC gene. Based on the ACMG guidelines, the variant was predicted to be likely pathogenic (PVS1+PM2_Supporting+PP4).
Conclusion: The heterozygous c.5044dupG variant of the FLNC gene probably underlay the pathogenesis in this patient, which has provided a basis for the genetic counseling for his family.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3760/cma.j.cn511374-20220606-00383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.
Eur Heart J
August 2025
Myocardial Homeostasis and Cardiac Injury Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Background: Truncating variants in the Filamin C gene (FLNCtv) are a frequent cause of genetic dilated cardiomyopathy (DCM) and non-dilated left ventricular cardiomyopathy (NDLVC), both characterized by arrhythmic complications and increased risk of sudden cardiac death. Currently, no gene-specific therapies exist for FLNCtv-induced cardiomyopathy. CRISPR activation (CRISPRa), which upregulates gene expression via transcriptional activation without cutting the genome, offers a promising strategy, particularly for genes like FLNC whose large size precludes conventional AAV-based gene replacement.
View Article and Find Full Text PDFRedefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.
Circulation
August 2025
Health in Code S.L., A Coruña, Spain; Spanish National Center for Cardiovascular Research (CNIC), Madrid, Spain.
Background: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder primarily linked to rare variants in sarcomere genes, though recently certain non-sarcomeric genes have emerged as important contributors. Non-Mendelian genetic variants with reproducible moderate effect sizes and low penetrance-intermediate-effect variants (IEVs)-, can play a crucial role in modulating disease expression. Understanding the clinical impact of IEVs is crucial to unravel HCM's complex genetic architecture.
View Article and Find Full Text PDFArrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure.
Eur Heart J
August 2025
Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Manuel de Falla 1, Majadahonda, 28222 Madrid, Spain.
Background And Aims: Certain genetic forms of dilated cardiomyopathy (DCM) entail a higher arrhythmic risk. It is unknown whether DCM patients with high-risk arrhythmic genotypes also develop more advanced heart failure (AHF) complications. AHF events were studied according to DCM genotype.
View Article and Find Full Text PDFPrognostic role of exercise intensity in familial Filamin C truncating variants.
Open Heart
August 2025
Cardiothoracovascular Department, Center for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste; European Reference Network for Rare, Low-Prevalence, and Complex Diseases of the Heart (ERN GUARD-Heart), Trieste, Italy.
Background: Truncating variants in the Filamin C () gene are causative of highly arrhythmogenic cardiomyopathies. Guidelines remain controversial concerning competitive and high-intensity sports for carriers. Indeed, the impact of high-intensity exercise on individuals carrying these variants remains poorly understood.
View Article and Find Full Text PDFIntroduction: Genetic variants are the leading cause of dilated cardiomyopathy (DCM). Data on genetic testing in DCM from Central European populations are scarce.
Objectives: We sought to determine the genetic architecture of DCM in Poland and assess its influence on clinical characteristics and prognosis.